These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26997353)

  • 1. Sensitivity to censored-at-random assumption in the analysis of time-to-event endpoints.
    Lipkovich I; Ratitch B; O'Kelly M
    Pharm Stat; 2016 May; 15(3):216-29. PubMed ID: 26997353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control-based imputation for sensitivity analyses in informative censoring for recurrent event data.
    Gao F; Liu GF; Zeng D; Xu L; Lin B; Diao G; Golm G; Heyse JF; Ibrahim JG
    Pharm Stat; 2017 Nov; 16(6):424-432. PubMed ID: 28834175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reference-based sensitivity analysis for time-to-event data.
    Atkinson A; Kenward MG; Clayton T; Carpenter JR
    Pharm Stat; 2019 Nov; 18(6):645-658. PubMed ID: 31309730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION.
    Bao W; Gaffney M; Pressler ML; Fayyad R; Wisemandle W; Beckerman B; Wolski KE; Nissen SE
    Clin Trials; 2020 Oct; 17(5):535-544. PubMed ID: 32643966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Missing data sensitivity analysis for recurrent event data using controlled imputation.
    Keene ON; Roger JH; Hartley BF; Kenward MG
    Pharm Stat; 2014; 13(4):258-64. PubMed ID: 24931317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models.
    Ratitch B; O'Kelly M; Tosiello R
    Pharm Stat; 2013; 12(6):337-47. PubMed ID: 23292975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations of multiple imputation approaches for handling missing data in clinical trials.
    Quan H; Qi L; Luo X; Darchy L
    Contemp Clin Trials; 2018 Jul; 70():62-71. PubMed ID: 29777866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting analysis time in events-driven clinical trials using accumulating time-to-event surrogate information.
    Wang J; Ke C; Yu Z; Fu L; Dornseif B
    Pharm Stat; 2016 May; 15(3):198-207. PubMed ID: 26689725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring event times in early phase clinical trials: some practical issues.
    Thall PF; Wooten LH; Tannir NM
    Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sizing clinical trials when comparing bivariate time-to-event outcomes.
    Sugimoto T; Hamasaki T; Evans SR; Sozu T
    Stat Med; 2017 Apr; 36(9):1363-1382. PubMed ID: 28120524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling and prediction of subject accrual and event times in clinical trials: a systematic review.
    Zhang X; Long Q
    Clin Trials; 2012 Dec; 9(6):681-8. PubMed ID: 22674642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating baseline measurements into the analysis of crossover trials with time-to-event endpoints.
    Xu R; Mehrotra DV; Shaw PA
    Stat Med; 2018 Oct; 37(23):3280-3292. PubMed ID: 29888552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of multiple ordinal endpoints.
    Häberle L; Pfahlberg A; Gefeller O
    Biom J; 2009 Feb; 51(1):217-26. PubMed ID: 19197963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment.
    Roger JH; Bratton DJ; Mayer B; Abellan JJ; Keene ON
    Pharm Stat; 2019 Jan; 18(1):85-95. PubMed ID: 30406948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A temporal correlation function for the association between patient-reported outcome and clinical endpoints.
    Gong Q; Fang L
    Pharm Stat; 2015; 14(5):377-81. PubMed ID: 26100118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.